Viking Therapeutics Stock News

According to Harvard University, about two-thirds of United States adults are “overweight or obese,” while 36% are obese. And the university predicts that, at the current rate, about 50% of Americ

While a weakening economy and a subsequent dip in the stock market are unfortunate, they are inevitabilities. Even booming segments like the biotech sector are not immune to the general trend of reces

Viking Therapeutics has been one of the few standouts in healthcare this year. The company's experimental weight loss candidate has fueled a sharp uptick in its share price over the prior 13 months.

Viking Therapeutics is developing two highly promising medicines. If the company succeeds, its share price will skyrocket even more.

If you follow Warren Buffett's advice of being greedy when others are fearful, then it probably makes sense to consider biotech stocks to buy on the dip. Primarily, the thesis centers on the underlyin

Investing in biotech stocks is not for the faint of heart. The sector is prone to wild swings in stock prices, offering a distinctive blend of high risk and high reward.

Shares of Pfizer and Viking Therapeutics have been on markedly different trajectories over the prior three years. In this comparison, Pfizer scans as a safer choice for cautious investors, while Vikin

The GLP-1 weight loss trend continues to flourish, and the ante keeps rising. The reigning champions in the battle of the bulge are Novo Nordisk A/V NYSE: NVO with its Semaglutide medications Ozempic

Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $63.42, signifying a -1.93% move from its prior day's close.

A couple of big-picture trends in biotech could add up to a nice investment opportunity. First, corporate buyouts are back in style.

Investors looking for a white-knuckle ride can easily find one by buying biotech stocks. There is a certain thrill in investing in a company making actual life-or-death decisions with drugs.

CRISPR Therapeutics has significant upside potential. Eli Lilly could become an even bigger healthcare giant.

Weight-loss stocks remain the focus of many investors. The GLP-1 drugs that many companies have put forward address key health concerns like obesity and diabetes, which have become epidemics in many W

Biotech stocks are one of the hottest investing opportunities in the stock marketlately. The optimism surrounding the industry is evident in the SPDR S&PBiotech ETF's (NYSEARCA: XBI ) 25% bump in valu

A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.